Evotec's Strategic Overhaul Comes at a Cost

All eyes are on April 8th, the date when Evotec will release its full-year 2025 report. This document is anticipated to provide the first comprehensive assessment of the company's ongoing "Horizon" restructuring initiative and its tangible impact on the business.

A Transitional Year with Declining Revenue

Preliminary figures for 2025 paint a picture of a company in transition. Group revenue is expected to reach €788 million, marking a decrease from the previous year. This decline was primarily driven by a significant 16% contraction in the Discovery segment, which fell to €529 million. The sole bright spot was the Biologics unit, Just Evotec Biologics, which posted robust growth of 40%, achieving revenue of €259 million.

The outlook for 2026 suggests this transitional phase will continue. Management forecasts a further revenue drop to a range between €700 million and €780 million. Adjusted EBITDA could potentially shrink to zero in a worst-case scenario. The market has reacted soberly to this forecast; Evotec's shares currently trade near €4.23, hovering just above their 52-week low of €4.14.

The "Horizon" Restructuring: Short-Term Pain for Long-Term Gain

At the core of Evotec's transformation is the "Horizon" program, a sweeping operational overhaul. The plan involves cutting up to 800 positions, consolidating the global footprint to ten key sites, and the complete closure of its Munich location. While the initial implementation carries a price tag of approximately €100 million, the company projects it will yield annual savings of around €75 million starting from late 2027.

Should investors sell immediately? Or is it worth buying Evotec?

Strategic Partnerships Provide Stability

To build a more resilient business model less susceptible to traditional market cycles, Evotec is actively pursuing strategic partnerships. A key development for its Biologics division is its selection by the BARDA BioMaP Consortium. The multi-year program focuses on advancing manufacturing optimization for a monoclonal antibody cocktail targeting filovirus diseases. The contract holds a potential total value of up to $10 million if all options are activated.

Such government-backed preparedness programs offer a degree of insulation from short-term commercial pressures, a valuable attribute for a platform undergoing significant change. Despite this, analyst sentiment remains cautious, as the weak profit guidance for 2026 continues to overshadow the near-term narrative.

Management Sets Ambitious Long-Term Targets

Looking beyond the current restructuring phase, Evotec's leadership has established ambitious medium-term goals. The company is targeting group revenues exceeding €1 billion by 2030. Furthermore, it aims to achieve an adjusted EBITDA margin of 20% by 2028. Initial positive operational effects from the "Horizon" program are expected to materialize in the second half of 2026.

Evotec at a turning point? This analysis reveals what investors need to know now.

The upcoming annual report on April 8th will be scrutinized for management commentary on cash burn and the concrete progress of the "Horizon" initiative. This information will be critical for investors gauging the realism of the company's stated timeline for recovery and growth.

Ad

Evotec Stock: New Analysis - 31 March

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

DE0005664809 | EVOTECS | boerse | 69033818 |